PK ! 1T T xl/worksheets/sheet1.xml
0
12
13
14
15
PK ! *]sc c xl/worksheets/sheet2.xml
6
7
89
1011
1213
1415
1617
1819
PK ! Ƹj! j! xl/worksheets/sheet3.xml
20
21
2223
8493105498533
24301543313578
25261456
27191562183499
289072677976
294818236379
3026960
3135821270
3228022575
33264500
343632048
354590757791
36
37-33885-39899
382088-5181
39794633
40-31003-44447
411490413344
42359-108173
4314545121517
44-7839-6450
456706115067
46
470.050.78
480.040.78
49
47148013147180
48151220147956
PK ! uc, , xl/worksheets/sheet4.xml
50
5152
53
54
55452097341378
5637175743
57530600638895
58497008490649
597513773467
6011021407
6115596611551539
62471165477754
63522758522814
6412629541304626
653239633947
662411024792
67674659541
682658676
691956122344
7039600704006033
71
72
73574322611867
742981744228
7566376474
7628833978
7730201794
78261000
79201007561
80636779676902
8127282122735264
823682836440
832843530182
842230823049
85618712318
862660193
8720611584
886378983365
8929435042972395
901307911804
91366708344932
9239600704006033
PK ! 5&. &. xl/worksheets/sheet5.xml
93
94
2223
95
9614545121517
97
985554958083
99-19705514
10021832004
101262416
10253304539
1031602115200
10414311266
105
57108385-60893
58-20283-2778
10626-110069
107602-26383
6030176
108-3722634839
10932603695
11014812849026
111
112-11776-7367
113-91726
11426-1050
11526-253625
116-12693-262042
117
11826180000
119-23630-7158
12026300000
12126-4102
1226765
123-2102-503
124-93-263
125-100026
126-26149467979
127-593-860
128108693254103
129347121152822
130455814406925
131452097405238
13237171687
130455814406925
PK ! F xl/worksheets/sheet6.xml
133
94
2223
9614545121517
134
373388539899
135359-108173
985554958083
136104338111326
134
13753304539
13857926978
1393632048
14011426
141262500
1423232475
143-20885181
144108862000
145999-2669
146126057134378
PK ! »
xl/worksheets/sheet7.xml
147
94
2223
9614545121517
134
14819721866
149359-108173
1503951440314
13753304539
13857926978
1393632048
14011426
141262500
1423232475
151265181
144108862000
145999-2669
152-17339-17005
153-1796-1239
1546106260332
1550.20.2
PK ! ( ( xl/worksheets/sheet8.xml
156
157158
159160161159160161
8312508162312508352586162352586
163185298-12019173279218865-14658204207
1642626261456-145626
271272101201913922913226516114148379
165166167168169
17018762-8241793816623-64115982
17136117-44503166729034-40228632
172262626960-96026
3135822635821265261265
1732626262500-250026
3480-802646-4626
356866917373860428183720663102500
PK ! 7 7 xl/worksheets/sheet9.xml
156
157158
159160161159160161
895931162959318797716287977
17448198-274932070547818-2544622372
27477332749375226401592544665605
165175176177178
17919881-5911929020942-185319089
18012065-761844477345-21415204
312626265265
332626262000262000
3515787357025148998672944039307
PK ! = xl/worksheets/sheet10.xml
156
157181
159160161159160161
884666162846665797016257970
24680472668047468952646895
27166192616619110752611075
165182182183183
18413704-6184752010788-64804308
185931-93126262626
3519847115909928764806767
PK ! \cP P xl/workbook.xml
PK ! mw# # xl/sharedStrings.xml
N/A☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))Maintaining Full Year 2021 Financial OutlookFull Year 2021 Financial GuidanceNet revenue$2.1 billion - $2.2 billionAdjusted EBITDA (1)$500 million - $540 millionAdjusted diluted EPS (2)$0.70 - $0.85Operating cash flow$220 million - $250 millionCapital expenditures$60 million - $70 millionWeighted average diluted shares outstanding (3)Approximately 303 millionConsolidated Statements of OperationsThree Months Ended
March 31,20212020Cost of goods soldCost of goods sold impairment charges—Gross profitSelling, general and administrativeResearch and developmentIn-process research and development impairment chargesIntellectual property legal development expensesAcquisition, transaction-related and integration expensesCharges related to legal matters, netRestructuring and other chargesOperating incomeOther (expense) income:Interest expense, netForeign exchange gain (loss), netOther income, netTotal other expense, netIncome before income taxesProvision for (benefit from) income taxesNet incomeLess: Net loss attributable to non-controlling interestsNet income attributable to Amneal Pharmaceuticals, Inc.Net income per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:BasicDilutedWeighted-average common shares outstanding:Condensed Consolidated Balance SheetsMarch 31, 2021December 31, 2020AssetsCurrent assets:Cash and cash equivalentsRestricted cashTrade accounts receivable, netInventoriesPrepaid expenses and other current assetsRelated party receivablesTotal current assetsProperty, plant and equipment, netGoodwillIntangible assets, netOperating lease right-of-use assetsOperating lease right-of-use assets - related partyFinancing lease right-of-use assetsFinancing lease right-of-use assets - related partyOther assetsTotal assetsLiabilities and Stockholders' EquityCurrent liabilities:Accounts payable and accrued expensesCurrent portion of long-term debt, netCurrent portion of operating lease liabilitiesCurrent portion of operating and financing lease liabilities - related partyCurrent portion of financing lease liabilitiesCurrent portion of note payable - related partyRelated party payable - short termTotal current liabilitiesLong-term debt, netNote payable - related partyOperating lease liabilitiesOperating lease liabilities - related partyFinancing lease liabilitiesFinancing lease liabilities - related partyRelated party payable - long termOther long-term liabilitiesTotal long-term liabilitiesRedeemable non-controlling interestsTotal stockholders' equityTotal liabilities and stockholders' equityConsolidated Statements of Cash FlowsThree Months Ended March 31,Cash flows from operating activities:Net incomeAdjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortizationUnrealized foreign currency (gain) lossAmortization of debt issuance costs and discountIntangible asset impairment chargesStock-based compensationInventory provisionOther operating charges and credits, netChanges in assets and liabilities:Income taxes receivable associated with the CARES ActPrepaid expenses, other current assets and other assetsAccounts payable, accrued expenses and other liabilitiesRelated party payablesNet cash provided by operating activitiesCash flows from investing activities:Purchases of property, plant and equipmentDeposit for future acquisition of property, plant and equipmentAcquisition of intangible assetsAcquisitions, net of cash acquiredNet cash used in investing activitiesCash flows from financing activities:Proceeds from issuance of debtPayments of principal on debt, financing leases and otherNet borrowings from revolving credit facilityPayments of deferred financing costsProceeds from exercise of stock optionsEmployee payroll tax withholding on restricted stock unit vestingPayments of principal on financing lease - related partyRepayment of related party noteNet cash (used in) provided by financing activitiesEffect of foreign exchange rate on cashNet increase in cash, cash equivalents, and restricted cashCash, cash equivalents, and restricted cash - beginning of periodCash, cash equivalents, and restricted cash - end of periodCash and cash equivalents - end of periodRestricted cash - end of periodReconciliation of Net Income to EBITDA and Adjusted EBITDAAdjusted to add (deduct):Income tax expense (benefit)EBITDA (Non-GAAP)Stock-based compensation expenseAcquisition and site closure expenses (1)Restructuring and other charges (2)Inventory related charges (3)Charges related to legal matters (4)Asset impairment charges (5)Foreign exchange (gain) lossResearch and development milestone paymentsOtherAdjusted EBITDA (Non-GAAP)Reconciliation of Net Income to Adjusted Net Income and Calculation of Adjusted Diluted EPSNon-cash interestGAAP Income tax expense (benefit)AmortizationForeign exchange loss (6)Income tax at 21%Net income attributable to non-controlling interests not associated with our Class B common stockAdjusted net income (Non-GAAP)Adjusted diluted EPS (Non-GAAP) (7)(Unaudited; In thousands)Three Months Ended March 31, 2021Three Months Ended March 31, 2020As ReportedAdjustmentsNon-GAAP$—Cost of goods sold (2)Cost of goods sold impairment charges (3)Gross margin %40.7%44.6%37.5%42.1%Selling, general and administrative (4)Research and development (5)In-process research and development impairment charges (6)Charges related to legal matters, net (7)Cost of goods sold (1)49.8%78.4%45.6%74.6%Selling, general and administrative (2)Research and development (3)Three Months Ended March 31, 2020 (2)19.6%19.1%Selling, general and administrative (3)Acquisition, transaction-related and integration expenses (4)PK !
R docProps/app.xml
Microsoft Excel0falseWorksheets10namaintaining full year 2021operationscondensed consolidated balcash flowsreconciliation of net incoreconciliation of net inco-1unaudited in thousandsunaudited in thousands-1unaudited in thousands-2falsefalsefalse12.0000PK ! B'P P docProps/core.xml
2021-05-07T10:48:16Z2021-05-07T10:48:16ZPK ! CfX X [Content_Types].xml
PK ! jq
xl/styles.xml
PK ! FTR R xl/theme/theme1.xml
PK ! IK K _rels/.rels
PK ! C_T xl/_rels/workbook.xml.rels
PK ! 1T T xl/worksheets/sheet1.xmlPK ! *]sc c xl/worksheets/sheet2.xmlPK ! Ƹj! j! # xl/worksheets/sheet3.xmlPK ! uc, , - xl/worksheets/sheet4.xmlPK ! 5&. &. Z xl/worksheets/sheet5.xmlPK ! F xl/worksheets/sheet6.xmlPK ! »
xl/worksheets/sheet7.xmlPK ! ( ( ; xl/worksheets/sheet8.xmlPK ! 7 7 xl/worksheets/sheet9.xmlPK ! = xl/worksheets/sheet10.xmlPK ! \cP P xl/workbook.xmlPK ! mw# # } xl/sharedStrings.xmlPK !
R @ docProps/app.xmlPK ! B'P P jE docProps/core.xmlPK ! CfX X G [Content_Types].xmlPK ! jq
rQ xl/styles.xmlPK ! FTR R NY xl/theme/theme1.xmlPK ! IK K t _rels/.relsPK ! C_T Ew xl/_rels/workbook.xml.relsPK 0